Lowering Costs by Improving Biosimilar Uptake Act

United States117th CongressHR-7047House of Representatives
Updated: Mar 10, 2022

Summary

Lowering Costs by Improving Biosimilar Uptake Act This bill allows for the omission of certain information relating to the strength of a product in a biosimilar application, as determined by the Food and Drug Administration.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in House

  2. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.